Plasticell Signs Deal with JCR Pharmaceuticals to Use CombiCult® Stem Cell Technology in Japan Plasticell has announced that it has signed a collaboration agreement with JCR Pharmaceuticals Co., Ltd. to discover custom stem cell culture media using its combinatorial stem cell technology, CombiCult®. [Plasticell] Press Release UConn Stem Cell Lines Go Global The University of Connecticut (UConn) signed an agreement with a global supplier of biological research tools to market stem cells to investigators studying genetic disorders around the world. The partnership with KeraFAST will ease the way for other institutions to obtain the cell lines, resulting in more widespread use in the research community. [University of Connecticut] Press Release Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines Alnylam Pharmaceuticals, Inc. announced that the previously announced alliance with Genzyme, a Sanofi company has closed, following the expiration of the Hart-Scott-Rodino waiting period. [Alnylam Pharmaceuticals, Inc.] Press Release BrainStorm Receives Additional $600,000 Non-Dilutive Grant from Israel’s Office of the Chief Scientist BrainStorm Cell Therapeutics Inc. announced that it was awarded an additional non-dilutive grant from Israel’s Office of the Chief Scientist for the year 2014 in the amount of $600,000. The grant is intended to support BrainStorm’s clinical development for its stem cell therapy candidate NurOwn™. [BrainStorm Cell Therapeutics Inc.] Press Release CEL-SCI Reports 146 Patients Enrolled in Its Phase III Immunotherapy Head and Neck Cancer Trial CEL-SCI Corporation reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date. [CEL-SCI Corporation] Press Release Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment from Its Phase Ib Study of PROHEMA(R) Fate Therapeutics, Inc. announced the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase Ib clinical trial of PROHEMA® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell transplantation for hematologic malignancy (the ProHema-01 trial). [Fate Therapeutics, Inc.] Press Release ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union ImmunoCellular Therapeutics, Ltd. announced that the European Medicines Agency has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. ICT-107 is an intradermally administered autologous vaccine consisting of the patient’s dendritic cells pulsed with six synthetic tumor-associated antigens: AIM-2, MAGE-1, TRP-2, gp100, HER-2, IL-13Rα2. [ImmunoCellular Therapeutics, Ltd.] Press Release Cardio3 BioSciences Strengthens IP Portfolio with New US Patent Cardio3 BioSciences announced that it has strengthened its IP portfolio following the United States Patent and Trademark Office issuing of a Notice of Allowance for patent application number US 12/994,626. The patent application covers compositions and methods for obtaining cells to treat heart tissue and specific parts of the Cardiopoiesis process by which Cardio3 BioSciences re-programs stem cells into cardiac progenitor cells during manufacturing. [Cardio3 BioSciences] Press Release Mediware Launches Transtem™ Patient 2014 Software for BMT Mediware Information Systems, Inc. announced the launch of the new Transtem Patient 2014 software for Blood and Marrow Transplant (BMT) programs. This single, specialized software solution allows transplant staff to efficiently manage patient, donor and product information all in one place, with the highest level of safety and security. [Mediware Information Systems, Inc.] Press Release GE Capital Provides Credit Facility to SynGen, Inc. GE Capital, Healthcare Financial Services announced that it has recently provided a $2.5 million senior secured credit facility to SynGen, Inc., a medical device company with a 510(k) approved bench-top system for isolating stem cells from umbilical cord blood, peripheral blood and bone marrow. [GE Capital, Healthcare Financial Services] Press Release |